Triple-negative breast cancer (TNBC), as defined by the absence of estrogen receptor (ER) and progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2), is a heterogeneous breast cancer subtype that carries the worst prognosis due to its aggressive characteristics and limited therapeutic options [1, 2]. This evidence concerns the gene PGR and breast carcinoma.